New B&L manager in Ireland

Article

Colum Honan is to be Bausch & Lomb's general manager with responsibility for its Waterford plant which manufactures contact lenses and other eye health products.

Colum Honan is to be Bausch & Lomb's general manager with responsibility for its Waterford plant which manufactures contact lenses and other eye health products.

He was previously deputy general manager and held a number of positions in which he managed successful projects where new products were taken from design to manufacturing to market launch.

Honan was involved with the successful transfer of the key new PureVision lens from the research and development stage to manufacturing.

In 1999, he was given responsibility as site leader for the industrialization of a new drug application which is now marketed as Retisert, a fluocinolone acetonide intravitreal implant, which represents a dramatic advance in the management of chronic non-infectious uveitis affecting the posterior segment of the eye.

He replaces Frank O'Regan, who last year was named vice president, Operations, Global Vision Care. Honan continues to report to O'Regan.

Welcoming the appointment, Frank O'Regan said: "Colum has a solid record of taking new products and processes from early product development phases right through to successful market launch with maximum efficiency. He takes over responsibility for the Waterford manufacturing site at a very challenging time when his management strengths will be a major asset in steering the business to a successful future."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.